Senseonics Holdings, Inc.
https://www.senseonics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Senseonics Holdings, Inc.
Senseonics Projects Slow Growth In 2022 Despite FDA Approval Of Eversense E3 CGM
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.
Market Intel: Glucose Monitor Market Set To Explode As Patients Access Better Devices
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
Medtronic Launches CGM-Integrated Smart Insulin Pen For Multiple Daily Injections
The announcement follows Medtronic’s acquisition of Companion Medical, which developed the first FDA-cleared insulin smart pen.
Market Brief: Abbott, Dexcom Help Drive Continuous Glucose Monitoring Market; 30% Expected Growth by 2023
Global sales of blood glucose monitoring devices are expected to reach $13bn by 2023, a CAGR of nearly 11%, led by the rising adoption of continuous glucose monitoring systems (CGMs). Abbott and Dexcom have been major drivers in the CGM market, but competition is fierce.
Company Information
- Industry
- Digital Health
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- ASN Technologies, Inc
- Sensors for Medicine and Science, Inc.
- Senseonics, Incorporated